CPE logo

CPE

Asia, Beijing, China, Beijing

Description

CPE, formerly known as CITIC Private Equity Funds Management, stands as a leading private equity firm in China, operating as the strategic onshore private equity platform of the vast CITIC Group. Established in 2008, CPE has rapidly grown to become a formidable force in the Chinese investment landscape, managing a substantial portfolio across various funds. The firm's investment strategy primarily focuses on growth equity and buyout opportunities within China, targeting sectors critical to the nation's economic transformation and consumption upgrade.

CPE's investment philosophy centers on long-term value creation, leveraging its deep industry insights, extensive network, and the robust resources of the CITIC Group. The firm is particularly active in high-growth sectors such as healthcare, advanced manufacturing, new consumption, and technology. They seek to partner with exceptional management teams, providing not just capital but also strategic guidance and operational support to help portfolio companies achieve sustainable growth and market leadership. Their approach often involves taking significant minority stakes or control positions in established companies with strong fundamentals and growth potential.

With an impressive asset under management (AUM) exceeding $20.7 billion as of December 2023, CPE has demonstrated its capacity to deploy significant capital into large-scale transactions. The firm has a strong track record of successful investments and exits, contributing to the development of key industries in China. Their disciplined investment process and commitment to post-investment value addition underscore their position as a preferred partner for companies seeking strategic capital for expansion and transformation.

Investor Profile

CPE has backed more than 34 startups, with 0 new investments in the last 12 months alone. The firm has led 9 rounds, about 26% of its total and boasts 25 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series C, Series B, Series D rounds (top funding stages).
  • Majority of deals are located in China, United States, Hong Kong.
  • Strong thematic focus on Health Care, Artificial Intelligence (AI), Transportation.
  • Typical check size: $50M – $350M.

Stage Focus

  • Series C (24%)
  • Series B (15%)
  • Series D (15%)
  • Private Equity (15%)
  • Series A (12%)
  • Series E (9%)
  • Series Unknown (6%)
  • Series G (3%)
  • Series F (3%)

Country Focus

  • China (91%)
  • United States (6%)
  • Hong Kong (3%)

Industry Focus

  • Health Care
  • Artificial Intelligence (Ai)
  • Transportation
  • Biotechnology
  • Autonomous Vehicles
  • E-commerce
  • Public Transportation
  • Manufacturing
  • Robotics
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does CPE frequently co-invest with?

CICC
Asia, Beijing, China, Beijing
Co-Investments: 3
Xiaomi
Asia, Beijing, China, Beijing
Co-Investments: 3
IDG Capital
Asia, Beijing, China, Beijing
Co-Investments: 5
Tencent
Asia, Guangdong, China, Shenzhen
Co-Investments: 3
GIC
Asia, Central Region, Singapore, Singapore
Co-Investments: 3
Temasek Holdings
Asia, Central Region, Singapore, Singapore
Co-Investments: 3
DST Global
Europe, England, United Kingdom, London
Co-Investments: 5
HongShan
Asia, Beijing, China, Beijing
Co-Investments: 7
Qiming Venture Partners
Asia, Shanghai, China, Shanghai
Co-Investments: 3
YF Capital
Asia, Shanghai, China, Jingan
Co-Investments: 3

Which angels does CPE often collaborate with?

Jun Lei
Asia, Beijing, China, Beijing
Shared Deals: 1

What are some of recent deals done by CPE?

Sangon Biotech

Shanghai, Shanghai, China

Sangon Biotech is engaged in the research and development of chemical synthesis of DNA.

BiotechnologyGenetics
Series UnknownApr 19, 2023
Amount Raised: $290,440,162
Jinyuansheng

Shanghai, Shanghai, China

Jinyuansheng is a supplier of new energy batteries.

Clean EnergyEnergy
Series BAug 15, 2022
Amount Raised: $147,634,163
Enflame

Shanghai, Shanghai, China

Enflame is an artificial intelligence start-up developing cloud-based deep learning chips for AI training platforms.

Artificial Intelligence (AI)Machine LearningSemiconductorSoftware
Series CAug 10, 2022
SiBionics

Shenzhen, Guangdong, China

SiBionics is a medtech company that engages in the field of chronic disease management.

Artificial Intelligence (AI)Health CareMedical Device
Series CJan 21, 2022
Amount Raised: $126,000,000
Chipone Technology

Beijing, Beijing, China

Chipone Technology is a chip design company engaged in the design of display chips for LED displays and LCD panels.

ElectronicsMobileProduct Design
Series EDec 15, 2021
Amount Raised: $1,020,792,763
GTA Semiconductor

Shanghai, Shanghai, China

GTA Semiconductor is a developer of semiconductor chips focusing on the R&D and design of integrated circuit related technologies.

ElectronicsManufacturingSemiconductor
Series UnknownNov 30, 2021
Amount Raised: $1,257,011,769
Wangdiantong

Beijing, Beijing, China

Wangdiantong is an E-commerce ERP management system that provides smart retail solutions for retailers digital transformation.

E-CommerceEnterprise Resource Planning (ERP)SaaS
Series DOct 28, 2021
Amount Raised: $312,000,000
Dreame Technology

Suzhou, Jiangsu, China

Dreame Technology produces premium hairdryers and vacuums in the style of Dyson.

ElectronicsManufacturingRetail
Series COct 21, 2021
Amount Raised: $563,089,484
Insilico Medicine

Hong Kong, Hong Kong Island, Hong Kong

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

Artificial Intelligence (AI)BiotechnologyHealth CarePharmaceutical
Series CJun 22, 2021
Amount Raised: $255,000,000
Biocytogen

Daxing, Beijing, China

Biocytogen is a biopharmaceutical company that provides integrated solutions for antibody drug development.

BiotechnologyHealth CareMedical DeviceTherapeutics
Series EJun 22, 2021